The allegations made by Chinese authorities against GlaxoSmithKline’s operations resemble those levelled at other pharmaceutical companies by the US Securities and Exchange Commission in the past, writes Tom Mitchell.
Of 14 Foreign Corrupt Practices Act cases settled by the SEC since January 2012, six involved the sale of pharmaceuticals or medical devices. Of these, three concerned operations in China.
Last August, the SEC alleged that Pfizer subsidiaries in China, Central Asia and Europe made “improper payments to foreign officials”.
您已閱讀32%（539字），剩余68%（1166字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。